x
Filter:
Filters applied
- JTO: Editors Choice
- COVID-19Remove COVID-19 filter
- SARS-CoV-2Remove SARS-CoV-2 filter
Publication Date
Please choose a date range between 2021 and 2021.
Author
- Assoun, Sandra1
- Benyounes, Amin1
- Bhardwaj, Nina1
- Bizot, Alexandra1
- Brouk, Zohra1
- Bucci, Enrico1
- Bunn, Paul A Jr1
- Carbone, Michele1
- Charpentier, Charlotte1
- Collin, Gilles1
- Descamps, Diane1
- Ferré, Valentine Marie1
- Fidouh, Nadhira1
- Flament, Héloïse1
- García-Sastre, Adolfo1
- Gomez, Jorge E1
- Gounant, Valérie1
- Henschke, Claudia I1
- Hirsch, Fred R1
- King, Jennifer1
- Krammer, Florian1
- Lednicky, John1
- Mack, Philip C1
- Meshulami, Noy1
- Minna, John D1
Editors Choice
3 Results
- Original Article SARS-CoV-2 Collection
Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses
Journal of Thoracic OncologyVol. 17Issue 2p239–251Published online: November 16, 2021- Valérie Gounant
- Valentine Marie Ferré
- Ghassen Soussi
- Charlotte Charpentier
- Héloïse Flament
- Nadhira Fidouh
- and others
Cited in Scopus: 29Coronavirus disease 2019 resulted in a 30% mortality rate in patients with thoracic cancer. Given that patients with cancer were excluded from serum antisevere acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccine registration trials, it is still unknown whether they would develop a protective antispike antibody response after vaccination. This prospective vaccine monitoring study primarily aimed to assess humoral responses to the SARS-CoV-2 vaccine in patients with thoracic cancer. - State of the Art: Concise Review SARS-CoV-2 Collection
Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation
Journal of Thoracic OncologyVol. 17Issue 2p214–227Published online: November 10, 2021- Christian Rolfo
- Noy Meshulami
- Alessandro Russo
- Florian Krammer
- Adolfo García-Sastre
- Philip C. Mack
- and others
Cited in Scopus: 10Patients with lung cancer are especially vulnerable to coronavirus disease 2019 (COVID-19) with a greater than sevenfold higher rate of becoming infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) COVID-19, a greater than threefold higher hospitalization rate with high complication rates, and an estimated case fatality rate of more than 30%. The reasons for the increased vulnerability are not known. In addition, beyond the direct impact of the pandemic on morbidity and mortality among patients with lung cancer, COVID-19, with its disruption of patient care, has also resulted in substantial impact on lung cancer screening and treatment/management.COVID-19 vaccines are safe and effective in people with lung cancer. - Special ArticleOpen Access
Coronavirus 2019 Infectious Disease Epidemic: Where We Are, What Can Be Done and Hope For
Journal of Thoracic OncologyVol. 16Issue 4p546–571Published online: January 7, 2021- Michele Carbone
- John Lednicky
- Shu-Yuan Xiao
- Mario Venditti
- Enrico Bucci
Cited in Scopus: 14Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spreads mainly by means of aerosols (microdroplets) in enclosed environments, especially those in which temperature and humidity are regulated by means of air-conditioning. About 30% of individuals infected with SARS-CoV-2 develop coronavirus disease 2019 (COVID-19) disease. Among them, approximately 25% require hospitalization. In medicine, cases are identified as those who become ill. During this pandemic, cases have been identified as those with a positive SARS-CoV-2 polymerase chain reaction test, including approximately 70% who were asymptomatic—this has caused unnecessary anxiety.